197 related articles for article (PubMed ID: 11242182)
1. Pneumocystis carinii pneumonia recurrence in HIV patients on highly active antiretroviral therapy: secondary prophylaxis.
Abgrall S; Matheron S; Le Moing V; Dupont C; Costagliola D;
J Acquir Immune Defic Syndr; 2001 Feb; 26(2):151-8. PubMed ID: 11242182
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group.
Weverling GJ; Mocroft A; Ledergerber B; Kirk O; Gonzáles-Lahoz J; d'Arminio Monforte A; Proenca R; Phillips AN; Lundgren JD; Reiss P
Lancet; 1999 Apr; 353(9161):1293-8. PubMed ID: 10218526
[TBL] [Abstract][Full Text] [Related]
3. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
[TBL] [Abstract][Full Text] [Related]
4. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy.
Schneider MM; Borleffs JC; Stolk RP; Jaspers CA; Hoepelman AI
Lancet; 1999 Jan; 353(9148):201-3. PubMed ID: 9923876
[TBL] [Abstract][Full Text] [Related]
5. A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to > 200 x 106 /l.
Koletar SL; Heald AE; Finkelstein D; Hafner R; Currier JS; McCutchan JA; Vallee M; Torriani FJ; Powderly WG; Fass RJ; Murphy RL;
AIDS; 2001 Aug; 15(12):1509-15. PubMed ID: 11504983
[TBL] [Abstract][Full Text] [Related]
6. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.
Ledergerber B; Mocroft A; Reiss P; Furrer H; Kirk O; Bickel M; Uberti-Foppa C; Pradier C; D'Arminio Monforte A; Schneider MM; Lundgren JD;
N Engl J Med; 2001 Jan; 344(3):168-74. PubMed ID: 11188837
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
[TBL] [Abstract][Full Text] [Related]
8. Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection. HIV Outpatient Study (HOPS) Investigators.
Yangco BG; Von Bargen JC; Moorman AC; Holmberg SD
Ann Intern Med; 2000 Feb; 132(3):201-5. PubMed ID: 10651600
[TBL] [Abstract][Full Text] [Related]
9. Pneumocystis carinii pneumonia after the discontinuation of secondary prophylaxis.
Degen O; ven Lunzen J; Horstkotte MA; Sobottka I; Stellbrink HJ
AIDS; 2002 Jul; 16(10):1433-4. PubMed ID: 12131226
[No Abstract] [Full Text] [Related]
10. Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count <200 cells/µL and virologic suppression: a systematic review.
Costiniuk CT; Fergusson DA; Doucette S; Angel JB
PLoS One; 2011; 6(12):e28570. PubMed ID: 22194853
[TBL] [Abstract][Full Text] [Related]
11. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study.
Furrer H; Egger M; Opravil M; Bernasconi E; Hirschel B; Battegay M; Telenti A; Vernazza PL; Rickenbach M; Flepp M; Malinverni R
N Engl J Med; 1999 Apr; 340(17):1301-6. PubMed ID: 10219064
[TBL] [Abstract][Full Text] [Related]
12. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study.
Saah AJ; Hoover DR; Peng Y; Phair JP; Visscher B; Kingsley LA; Schrager LK
JAMA; 1995 Apr; 273(15):1197-202. PubMed ID: 7707627
[TBL] [Abstract][Full Text] [Related]
13. Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells/microl when viral replication is suppressed.
D'Egidio GE; Kravcik S; Cooper CL; Cameron DW; Fergusson DA; Angel JB
AIDS; 2007 Aug; 21(13):1711-5. PubMed ID: 17690568
[TBL] [Abstract][Full Text] [Related]
14. Pneumocystis carinii pneumonia in the Federal Republic of Germany in the era of changing antiretroviral therapy - IDKF 13 -. German AIDS Study Group (GASG/IdKF).
Stoehr A; Arasteh K; Staszewski S; Brockmeyer N; Albrecht H; Mertenskötter T; Jablonowski H; Emminger C; Rockstroh JK; Baumgarten R; Bogner J; Loch T; Plettenberg A
Eur J Med Res; 1999 Apr; 4(4):131-4. PubMed ID: 10205287
[TBL] [Abstract][Full Text] [Related]
15. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997.
Jones JL; Hanson DL; Dworkin MS; Alderton DL; Fleming PL; Kaplan JE; Ward J
MMWR CDC Surveill Summ; 1999 Apr; 48(2):1-22. PubMed ID: 12412613
[TBL] [Abstract][Full Text] [Related]
16. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety of discontinuation of secondary prophylaxis against Pneumocystis pneumonia: prospective multicentre study.
Zellweger C; Opravil M; Bernasconi E; Cavassini M; Bucher HC; Schiffer V; Wagels T; Flepp M; Rickenbach M; Furrer H;
AIDS; 2004 Oct; 18(15):2047-53. PubMed ID: 15577626
[TBL] [Abstract][Full Text] [Related]
18. Discontinuation of primary prophylaxis in HIV-infected patients at high risk of Pneumocystis carinii pneumonia: prospective multicentre study.
Furrer H; Opravil M; Rossi M; Bernasconi E; Telenti A; Bucher H; Schiffer V; Boggian K; Rickenbach M; Flepp M; Egger M;
AIDS; 2001 Mar; 15(4):501-7. PubMed ID: 11242147
[TBL] [Abstract][Full Text] [Related]
19. Occurrence of Pneumocystis carinii pneumonia in HIV-1-infected patients responding to HAART: is prophylaxis discontinuation a safe tool?
Mezzaroma I; Giovannetti A; Pinter E; Ensoli F; Aiuti F
AIDS; 1999 Dec; 13(17):2488-9. PubMed ID: 10597798
[No Abstract] [Full Text] [Related]
20. Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaluation Working Group.
Simonds RJ; Lindegren ML; Thomas P; Hanson D; Caldwell B; Scott G; Rogers M
N Engl J Med; 1995 Mar; 332(12):786-90. PubMed ID: 7862183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
